109 related articles for article (PubMed ID: 31584572)
1. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Goldsmith SR; Lovell AR; Schroeder MA
Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
Lin S; Shaik N; Chan G; Cortes JE; Ruiz-Garcia A
Cancer Chemother Pharmacol; 2020 Oct; 86(4):451-459. PubMed ID: 32885274
[TBL] [Abstract][Full Text] [Related]
3. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
[TBL] [Abstract][Full Text] [Related]
4. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
6. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
[TBL] [Abstract][Full Text] [Related]
7. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
[TBL] [Abstract][Full Text] [Related]
8. New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Daver N; Wei AH; Pollyea DA; Fathi AT; Vyas P; DiNardo CD
Blood Cancer J; 2020 Oct; 10(10):107. PubMed ID: 33127875
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia.
Smoljo T; Tomic B; Lalic H; Dembitz V; Batinic J; Bedalov A; Visnjic D
Front Pharmacol; 2023; 14():1258151. PubMed ID: 37954840
[TBL] [Abstract][Full Text] [Related]
10. A comparative safety review of targeted therapies for acute myeloid leukemia.
Dalgetty M; Leurinda C; Cortes J
Expert Opin Drug Saf; 2023; 22(12):1225-1236. PubMed ID: 38014918
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia in the medically unfit elderly patients.
Edmund J; Thaliath LJ; Meleveedu K
Leuk Res; 2023 Jul; 130():107306. PubMed ID: 37163857
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Kubasch AS; Peterlin P; Cluzeau T; Götze KS; Sockel K; Teipel R; Jentzsch M; Attalah H; Sebert M; Chermat F; Gloaguen S; Puttrich M; Cross M; Schneider M; Kayser S; Schipp D; Giagounidis A; Tirado-Gonzalez I; Descot A; van de Loosdrecht A; Weigert A; Metzeler KH; Fenaux P; Medyouf H; Platzbecker U; Ades L
Leukemia; 2023 Nov; 37(11):2309-2313. PubMed ID: 37735558
[No Abstract] [Full Text] [Related]
13. Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.
Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Eissymont O; Crysandt M; Görner M; Kayser S; Krause S; Schliemann C; Gaska T; Kaufmann M; Chemnitz J; Schaich M; Hoellein A; Platzbecker U; Kieser M; Müller-Tidow C; Schlenk RF
Haematologica; 2024 Feb; 109(6):1973-6. PubMed ID: 38385304
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E; Lee CJ; Caballero-Velázquez T; Martínez C; García-Calderón C; Jiménez-León MR; Bermúdez-Rodríguez MA; López-Corral L; Triguero A; Onstad L; Horwitz ME; Sarantopoulos S; Lee SJ; Pérez-Simón JA
Clin Cancer Res; 2023 Oct; 29(20):4057-4067. PubMed ID: 37698881
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Thomas X; Heiblig M
Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
[No Abstract] [Full Text] [Related]
16. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
17. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice.
Kleinrok Z; Matuszek M; Jesipowicz J; Matuszek B; Opolski A; Radzikowski C
J Physiol Pharmacol; 1998 Jun; 49(2):303-10. PubMed ID: 9670113
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
Ruiz-Garcia A; Shaik N; Lin S; Jamieson C; Heuser M; Chan G
J Clin Pharmacol; 2021 Mar; 61(3):349-359. PubMed ID: 32974950
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
